STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item		X
	No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used	Title page
		term in the title or the abstract	& Page 1
		(b) Provide in the abstract an informative and	Page 1
		balanced summary of what was done and what was	
		found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	Page 2
		investigation being reported	
Objectives	3	State specific objectives, including any prespecified	Page 3
		hypotheses	
Methods			
Study design	4	Present key elements of study design early in the	Page 3
		paper	
Setting	5	Describe the setting, locations, and relevant dates,	Page 3-4
		including periods of recruitment, exposure, follow-up,	
		and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and	Page 3
		methods of selection of participants	
Variables	7	Clearly define all outcomes, exposures, predictors,	Page 4
		potential confounders, and effect modifiers. Give	
		diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and	Page 3-5
measurement		details of methods of assessment (measurement).	
		Describe comparability of assessment methods if there	
		is more than one group	
Bias	9	Describe any efforts to address potential sources of	Page 5
		bias	
Study size	10	Explain how the study size was arrived at	Page 3
Quantitative	11	Explain how quantitative variables were handled in	Page 4
variables		the analyses. If applicable, describe which groupings	
		were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those	Page 5
		used to control for confounding	
		(b) Describe any methods used to examine subgroups	Page 4
		and interactions	
		(c) Explain how missing data were addressed	Page 5
		(d) If applicable, describe analytical methods taking	NA NA
		account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
Results		()	

		eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	Page 6
		(c) Consider use of a flow diagram	Page 6
Descriptive data	14*	(a) Give characteristics of study participants (eg	Page 7
		demographic, clinical, social) and information on	8
		exposures and potential confounders	
		(b) Indicate number of participants with missing data	Page 6
		for each variable of interest	8
Outcome data	15*	Report numbers of outcome events or summary	Page 7
	10	measures	1 480 /
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 7-8
		(b) Report category boundaries when continuous	Page 7
		variables were categorized	
		(c) If relevant, consider translating estimates of	NA
		relative risk into absolute risk for a meaningful time	
		period	
Other analyses	17	Report other analyses done—eg analyses of subgroups	Page 7
		and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 7-8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 11
Interpretation	20	Give a cautious overall interpretation of results	Page 8-10
		considering objectives, limitations, multiplicity of	
		analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the	Page 10-11
		study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 12

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.